Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Vie Ventures is a venture capital firm founded in July 2025 by Steven St. Peter, MD, and Luke Evnin, PhD, in Cambridge, Massachusetts. The firm specializes in the intersection of life sciences venture capital and disease philanthropy, focusing on developing innovative therapeutics for autoimmune diseases and disorders of the immune system. The firm aims to create a significant impact in the biotech sector by aligning financial returns with mission-driven initiatives.
Currently, Vie Ventures operates from its office located at 245 Main Street, Floor 2, Cambridge, MA 02142. The firm has established the Vie Ventures Foundation, a public charity, and convened a Therapeutics Advisory Council that collaborates with major autoimmune disease organizations. This strategic approach allows Vie Ventures to leverage insights from patient experts and disease ecosystems to inform its investment decisions.
Vie Ventures invests primarily in therapeutic companies that are developing next-generation therapies and cures for autoimmune diseases. The firm targets Series B and C-stage private biotech companies, emphasizing a returns-oriented model that aligns with purpose-driven capital. The investment strategy includes leveraging collaborations with disease-focused philanthropies and strategic partners within the biotech ecosystem.
The firm seeks to generate financial returns while making a mission-driven impact. Vie Ventures is particularly interested in companies that bridge the gap between traditional venture capital and disease philanthropy, ensuring that their investments contribute positively to the healthcare landscape.
Steven St. Peter, M.D. - Co-Founder & Managing Director. Previously co-managed three successive funds at MPM Capital, bringing extensive experience in life sciences.
Luke Evnin, Ph.D. - Co-Founder & Managing Director. Also a former co-manager at MPM Capital, he has a strong background in biotech investments.
Jeff Bluestone, Ph.D. - Managing Director, joined in February 2026. A pioneer in Treg biology, he adds significant expertise to the firm.
Lou DeGennaro, Ph.D. - Senior Advisor. Former CEO of the Leukemia & Lymphoma Society, he provides strategic insights into the biotech sector.
Shane Bates - CFO, responsible for financial oversight and strategy.
Steven Neier, Ph.D. - Consultant, contributing scientific expertise to investment evaluations.
Jolyon Martin, Ph.D. - Investment Team Member, involved in sourcing and evaluating potential investments.
Casey Hill - Fundraising Coordinator, managing investor relations and fundraising efforts.
To pitch Vie Ventures, founders should send an email to contact@vieventures.com with a detailed pitch deck. The deck should include information on the company's mission, therapeutic innovations, market analysis, and team qualifications. Response times may vary, but founders are encouraged to follow up if they do not receive a timely reply.
In February 2026, Jeff Bluestone, Ph.D., joined Vie Ventures as Managing Director, enhancing the firm's expertise in Treg biology. The firm also announced the establishment of the Therapeutics Advisory Council in September 2025, which collaborates with major autoimmune disease organizations.
Vie Ventures launched in July 2025, with a mission to bridge venture capital and disease philanthropy, focusing on innovative therapeutics for autoimmune diseases.
What are Vie Ventures' investment criteria?
Vie Ventures focuses on therapeutic companies developing innovative solutions for autoimmune diseases. They primarily invest in Series B and C-stage biotech firms.
How can I pitch to Vie Ventures?
Founders can reach out via email at contact@vieventures.com. A well-prepared pitch deck that outlines the company's vision, market potential, and therapeutic innovations is recommended.
What makes Vie Ventures different from other VCs?
Vie Ventures uniquely combines venture capital with disease philanthropy, leveraging partnerships with major autoimmune disease organizations to inform their investment decisions.
What is the geographic focus of Vie Ventures?
The firm primarily invests in North America, targeting biotech companies that align with their mission-driven investment strategy.
What is the typical check size for investments?
While specific check sizes are not disclosed, Vie Ventures focuses on Series B and C investments, which typically range from several million to tens of millions of dollars.
What kind of post-investment involvement can founders expect?
Vie Ventures engages actively with portfolio companies, providing strategic guidance and leveraging their network of disease-focused organizations to support growth and development.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.